anurajms/meta_analysis huggingface dataset:
outcomes:
Cognitive‐behavioural treatment for amphetamine‐type stimulants (ATS)‐use disorders
1. Substance Use 2. Abstinent From Drug Misuse
outcomes:
Antidepressants for the treatment of people with co‐occurring depression and alcohol dependence
1. Elevated Liver Enzyme Levels 2. Suicide Attempt 3. Depression 4. Clinician-Reported Outcome 5. Suicide 6. Clinical Improvement 7. Alcohol Use
outcomes:
Effectiveness of brief alcohol interventions in primary care populations
1. Finding Of Frequency Of Drinking 2. Patient-Reported Outcome
outcomes:
Personalised digital interventions for reducing hazardous and harmful alcohol consumption in community‐dwelling populations
1. Binge drinking 2. Alcohol Use
outcomes:
Opioid antagonists with minimal sedation for opioid withdrawal
1. Withdrawal syndrome
outcomes:
Supervised dosing with a long‐acting opioid medication in the management of opioid dependence
1. Abstinent From Drug Misuse
outcomes:
Psychostimulant drugs for cocaine dependence
1. Abstinent From Drug Misuse
outcomes:
Psychosocial interventions for cannabis use disorder
1. Cannabis Use 2. Cannabis-induced Organic Mental Disorder 3. Patient-Reported Outcome
outcomes:
Alpha2‐adrenergic agonists for the management of opioid withdrawal
1. Withdrawal syndrome
outcomes:
Antipsychotic medications for cocaine dependence
1. Cocaine Abuse
outcomes:
Dopamine agonists for the treatment of cocaine dependence
1. Abstinent From Drug Misuse
outcomes:
Anticonvulsants for cocaine dependence
1. Drug Craving 2. Substance Use 3. Adverse Drug Reaction
outcomes:
Universal school‐based prevention for illicit drug use
1. Substance Use 2. Cannabis Use
outcomes:
Restricting or banning alcohol advertising to reduce alcohol consumption in adults and adolescents
1. Advertising revenue 2. Decreased Alcohol Consumption 3. Alcohol Intake 4. Alcohol related injury
outcomes:
Maintenance treatments for opiate ‐dependent adolescents
1. Withdrawn From Research Study 2. Substance Use 3. Relapse 4. Patient-Reported Outcome
outcomes:
Anticonvulsants for alcohol dependence
1. Follow-up Visit 2. Safety Finding 3. Efficacy 4. Heavy drinking 5. Acceptability of treatment 6. Adverse Event 7. Abstinent Alcoholic
outcomes:
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
1. Substance Use
outcomes:
Efficacy of psychostimulant drugs for amphetamine abuse or dependence
1. Long-term abstinence 2. Amphetamine Abuse
outcomes:
Bladder training for treating overactive bladder in adults
1. Quality of Life 2. Adverse Event 3. Patient-Reported Outcome
outcomes:
Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women
1. Serious Adverse Event 2. Quality of Life 3. Genital prolapse 4. Adverse Event 5. Patient compliance 6. Sexual function
outcomes:
Conservative interventions for managing urinary incontinence after prostate surgery
1. International Consultation On Incontinence Questionnaire Short Form 2. Quality of Life 3. Clinical Improvement
outcomes:
Transurethral microwave thermotherapy for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
1. Retreatment 2. Urological Test Finding 3. Finding Of Ejaculation 4. Quality of Life 5. Adverse Event 6. Erectile function
outcomes:
Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic obstruction
1. Surgery 2. Urologicals 3. Quality of Life 4. Acute Retention Of Urine 5. Adverse Event
outcomes:
Convective radiofrequency water vapour thermal therapy for lower urinary tract symptoms in men with benign prostatic hyperplasia
1. Erectile Dysfunction 2. Serious Adverse Event 3. Urological Test Finding 4. Finding Of Ejaculation 5. Quality of Life 6. Connective Radiofrequency Water Vapour Thermal Therapy
outcomes:
Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction
1. Erectile Dysfunction 2. Transurethral resection syndrome 3. Blood Transfusion 4. Repeat surgery 5. Urological Test Finding 6. Urinary Incontinence 7. Transurethral Prostatectomy 8. Health-Related Quality of Life 9. International Prostate Symptom Score
outcomes:
Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
1. Sexual Health Inventory For Men 2. Serious Adverse Event 3. Repeat surgery 4. Finding Of Ejaculation 5. Quality of Life 6. Lower urinary tract symptoms 7. Erectile function
outcomes:
Physical activity for lower urinary tract symptoms secondary to benign prostatic obstruction
1. Withdrawal Due To Adverse Events 2. Lower urinary tract symptoms 3. Therapeutic Response 4. Clinical Improvement
outcomes:
Antimicrobial agents for preventing urinary tract infections in adults undergoing cystoscopy
1. Serious Adverse Event 2. Bacterial Resistance 3. Urinary Tract Infection 4. Adverse Event
outcomes:
Ureteral stent versus no ureteral stent for ureteroscopy in the management of renal and ureteral calculi
1. Postoperative Pain 2. Stricture Of Ureter 3. Emergency Care 4. Surgery 5. Opioids 6. Visual Analog Scale 7. Urinary Tract Infection 8. Hospitalization
outcomes:
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia
1. Benign Prostatic Hyperplasia Impact Index 2. Adverse Event 3. International Prostate Symptom Score
outcomes:
Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
1. Treatment Withdrawal 2. Cardiovascular Event 3. Quality of Life 4. Lower urinary tract symptoms 5. Sexual function
outcomes:
Non‐pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome
1. Chronic Prostatitis - Chronic Pelvic Pain Syndrome 2. Sexual dysfunction 3. Quality of Life 4. Depression 5. Anxiety 6. Adverse Event
outcomes:
Electrical stimulation with non‐implanted devices for stress urinary incontinence in women
1. Treatment Success 2. Quality of Life 3. Stress urinary incontinence 4. Clinical Improvement 5. Patient-Reported Outcome
outcomes:
Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
1. Treatment Withdrawal 2. Cardiovascular Event 3. Sexual dysfunction 4. Quality of Life 5. Lower urinary tract symptoms
outcomes:
Desmopressin for treating nocturia in men
1. Serious Adverse Event 2. Sleep Finding 3. Quality of Life 4. Withdrawal Due To Adverse Events 5. Adverse Event 6. Time-to-Event 7. Nocturia
outcomes:
Surgery versus non‐surgical management for unilateral ureteric‐pelvic junction obstruction in newborns and infants less than two years of age
1. Obstruction Of Pelviureteric Junction 2. Renal Function Monitoring 3. Clinical Improvement 4. Upper Urinary Tract Dilatation And Obstruction
outcomes:
Antimicrobial therapy for chronic bacterial prostatitis
1. Microbial Culture Finding 2. Clinical Resolution 3. Adverse Event 4. Clinical Improvement
outcomes:
Reconstructive surgery for treating pressure ulcers
1. Pressure ulcer 2. Wound Healing 3. Wound Dehiscence
outcomes:
Timing of antibiotic administration, wound debridement, and the stages of reconstructive surgery for open long bone fractures of the upper and lower limbs
1. Infection 2. Quality Of Life Scale 3. Deep Incisional Surgical Site Infection 4. Euroqol Five Dimension Questionnaire 5. Short Form Health Survey - 36 6. Sickness Impact Profile 7. Disability Rating Scale 8. Health-Related Quality of Life 9. Patient-Reported Outcome
outcomes:
Reactive air surfaces for preventing pressure ulcers
1. Costs and Cost Analysis 2. Pressure ulcer 3. Adverse Event 4. Health-Related Quality of Life
outcomes:
Intracavity lavage and wound irrigation for prevention of surgical site infection
1. Surgical Site Infection 2. Abscess 3. Adverse Event 4. Wound Dehiscence
outcomes:
Topical phenytoin for treating pressure ulcers
1. Pain 2. Wound Healing 3. Adverse Event
outcomes:
Interventions for treating gas gangrene
1. Infection 2. Quality of Life 3. Death 4. Gas Gangrene 5. Limb amputation
outcomes:
Dressings and securement devices for central venous catheters (CVC)
1. Catheter Related Infection 2. Central Venous Catheter Related Bloodstream Infection 3. Bacterial Colonization
outcomes:
Devices and dressings to secure peripheral venous catheters to prevent complications
1. Catheter Dislodgment 2. Removal Of Catheter 3. Treatment Failure 4. Phlebitis 5. Peripherally Inserted Central Catheterization 6. Adverse Event
outcomes:
Perioperative corticosteroids for preventing complications following facial plastic surgery
1. Edema 2. Pain 3. Swelling 4. Bruising 5. Time to complete wound healing
outcomes:
Continuous versus interrupted skin sutures for non‐obstetric surgery
1. Surgical Site Infection 2. Length for Age Z-Score 3. Quality of Life 4. Wound Dehiscence
outcomes:
Pin site care for preventing infections associated with external bone fixators and pins
1. Infection 2. Replacement Procedure 3. All Cause Mortality 4. Healthcare costs 5. Removal Of External Fixator Pin 6. Patient comfort 7. Limb amputation
outcomes:
Systemic antimicrobial prophylaxis for percutaneous endoscopic gastrostomy
1. Peristomal Fistula
Provide patient population that should be included in the study
Skin care interventions in infants for preventing eczema and food allergy
1. Infant 1 to 23 mo 2. Birth to 1 mo
Provide patient population that should be included in the study
Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Cystic Fibrosis 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Multiple chronic conditions 9. Adult 19-44 years 10. Middle Aged 45-64 years 11. Allergic Bronchopulmonary Aspergillosis 12. Young Adult 19-24 years 13. Birth to 1 mo
Provide patient population that should be included in the study
Anti‐IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Allergic Bronchopulmonary Aspergillosis 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Whole‐cell pertussis vaccine in early infancy for the prevention of allergy in children
1. Child 6-12 years 2. Infant 1 to 23 mo 3. Birth to 1 mo
Provide patient population that should be included in the study
High versus low medium chain triglyceride content of formula for promoting short‐term growth of preterm infants
1. Birth to 1 mo 2. Infant Formula With Medium Chain Triglycerides 3. Preterm Infant
Provide patient population that should be included in the study
Sublingual immunotherapy for asthma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Asthma
Provide patient population that should be included in the study
Dilute versus full‐strength formula in exclusively formula‐fed preterm or low birth weight infants
1. Enteral nutrition 2. Partially hydrolysed infant formula 3. Birth to 1 mo 4. Low Birth Weight Infant 5. Preterm Infant
Provide patient population that should be included in the study
Probiotics for treating eczema
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Eczema 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Infant formulas containing hydrolysed protein for prevention of allergic disease
1. Infant 1 to 23 mo 2. Birth to 1 mo
Provide patient population that should be included in the study
Oral and sublingual immunotherapy for egg allergy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Egg Protein Allergy 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy
1. Birth to 1 mo
Provide patient population that should be included in the study
Specific allergen immunotherapy for the treatment of atopic eczema
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Atopic Dermatitis 5. Food Allergen Sensitization 6. Young Adult 19-24 years 7. Positive Skin Test 8. Allergic Inhalant Dermatitis 9. Radioallergosorbent Test 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Immunotherapy (oral and sublingual) for food allergy to fruits
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Allergy To Fruit 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Glycerin laxatives for prevention or treatment of feeding intolerance in very low birth weight infants
1. Birth to 1 mo 2. Very Low Birth Weight Infant 3. Enteral Feeding Intolerance 4. Preterm Infant
Provide patient population that should be included in the study
Maternal prenatal and/or postnatal n‐3 long chain polyunsaturated fatty acids (LCPUFA) supplementation for preventing allergies in early childhood
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Infant 1 to 23 mo 5. Lactating Breast 6. Young Adult 19-24 years 7. Pregnancy 8. Birth to 1 mo
Provide patient population that should be included in the study
H1‐antihistamines for chronic spontaneous urticaria
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Chronic spontaneous urticaria 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Omalizumab for asthma in adults and children
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Asthma
Provide patient population that should be included in the study
Prebiotics in infants for prevention of allergy
1. Birth to 1 mo
Provide patient population that should be included in the study
Lactase treated feeds to promote growth and feeding tolerance in preterm infants
1. Birth to 1 mo 2. Preterm Infant
Provide patient population that should be included in the study
Oral H1 antihistamines as monotherapy for eczema
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Eczema 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta thalassaemia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Beta Thalassemia 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Blood Product Transfusion Dependent 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Topical repellents for malaria prevention
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Malaria-endemic area
Provide patient population that should be included in the study
Interventions for chronic kidney disease in people with sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Hemoglobin SS Disease 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Rapamycin and rapalogs for tuberous sclerosis complex
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Tuberous Sclerosis Syndrome 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or bone marrow transplantation in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Blood disorders 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Allogeneic Stem Cell Transplantation 7. Aged 65-79 years
Provide patient population that should be included in the study
Treatment for osteoporosis in people with beta‐thalassaemia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Osteoporosis 6. Middle Aged 45-64 years 7. Beta Thalassemia 8. Infant 1 to 23 mo 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Treatment of dental and orthodontic complications in thalassaemia
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Thalassemia 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Non-transfusion dependent thalassaemia 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Laser therapy for retinopathy in sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Proliferative Retinopathy Due To Sickle Cell Disease 10. Aged 65-79 years 11. Hemoglobin SS Disease 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Acute Chest Syndrome 10. Aged 65-79 years 11. Hemoglobin SS Disease 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Extracorporeal photopheresis versus standard treatment for acute graft‐versus‐host disease after haematopoietic stem cell transplantation in children and adolescents
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Hemopoietic Stem Cell Transplant 5. Birth to 1 mo 6. Acute Graft-versus-host Disease 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Hydroxyurea (hydroxycarbamide) for sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Hemoglobin SS Disease 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Inhaled nitric oxide for treating pain crises in people with sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Sickle Cell Disease 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Malaria 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta‐analysis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Solid Tumor 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Hematological Malignancy 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Extracorporeal photopheresis versus alternative treatment for chronic graft‐versus‐host disease after haematopoietic stem cell transplantation in children and adolescents
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Hemopoietic Stem Cell Transplant 5. Birth to 1 mo 6. Adolescent 13-18 years 7. Chronic Graft-versus-host Disease
Provide patient population that should be included in the study
Indoor residual spraying for preventing malaria in communities using insecticide‐treated nets
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years 11. Malaria-endemic area
Provide patient population that should be included in the study
Angiotensin‐converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Adult 19-44 years 8. Middle Aged 45-64 years 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Hemoglobin SS Disease 12. Microalbuminuria 13. Proteinuria
Provide patient population that should be included in the study
Maternal and foetal outcomes following natural vaginal versus caesarean section (c‐section) delivery in women with bleeding disorders and carriers
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Blood Coagulation Disorder 4. Young Adult 19-24 years 5. Pregnancy 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay‐Sachs disease
1. Carrier Of Cystic Fibrosis Gene Mutation 2. Adult 19-44 years 3. Carrier Of Tay Sachs Disease Gene Mutation 4. Middle Aged 45-64 years 5. Carrier Of Sickle Cell Gene Mutation 6. Carrier of Thalassemia Mutation 7. Young Adult 19-24 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Recombinant growth hormone therapy for X‐linked hypophosphatemia in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. X-linked hypophosphatemia 5. Birth to 1 mo 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Mass drug administration for malaria
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Prevention Of Malaria 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years 11. Maroteaux-lamy Syndrome
Provide patient population that should be included in the study
Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Diffuse large B-cell lymphoma refractory 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Rituximab for eradicating inhibitors in people with acquired haemophilia A
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Haemophilia 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated individuals with haemophilia A or B
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Haemophilia 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Intermittent preventive treatment for malaria in infants
1. Infant 1 to 23 mo 2. Malaria 3. Birth to 1 mo
Provide patient population that should be included in the study
Hematopoietic stem cell transplantation for people with β‐thalassaemia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Beta Thalassemia 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Thalassemia Major 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Disease‐modifying treatments for primary autoimmune haemolytic anaemia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Primary (idiopathic) Autoimmune Hemolytic Anemia 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Sickle Cell-beta-thalassemia 4. Infant 1 to 23 mo 5. Birth to 1 mo 6. Hemoglobin SS Disease 7. Adolescent 13-18 years 8. Sickle Cell-hemoglobin C Disease
Provide patient population that should be included in the study
Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Falciparum Malaria 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for treating leg ulcers in people with sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Leg Ulcer 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Hemoglobin SS Disease 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Tyrosine supplementation for phenylketonuria
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Phenylketonuria 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Paediatric formulations of artemisinin‐based combination therapies for treating uncomplicated malaria in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Malaria 5. Birth to 1 mo 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Gene therapy for sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Hemoglobin SS Disease 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Phytomedicines (medicines derived from plants) for sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Beta Thalassemia 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Hemoglobin SS Disease 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Rituximab for treating inhibitors in people with inherited severe hemophilia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Adult 19-44 years 8. Middle Aged 45-64 years 9. Factor Ix Inhibitor Disorder 10. Haemophilia 11. Young Adult 19-24 years 12. Birth to 1 mo 13. Factor VIII Inhibitor Disorder
Provide patient population that should be included in the study
Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Hemoglobin SS Disease 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Dietary interventions for phenylketonuria
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Phenylketonuria 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for mycosis fungoides
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Mycosis Fungoides 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Hematopoietic stem cell transplantation for people with sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Hemoglobin SS Disease 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Preoperative blood transfusions for sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Beta Thalassemia 5. Infant 1 to 23 mo 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Adult 19-44 years 9. Middle Aged 45-64 years 10. Young Adult 19-24 years 11. Birth to 1 mo 12. Hemoglobin SS Disease 13. Sickle Cell-hemoglobin C Disease
Provide patient population that should be included in the study
Interventions for treating intrahepatic cholestasis in people with sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Intrahepatic Cholestasis 10. Aged 65-79 years 11. Hemoglobin SS Disease 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Growth hormone therapy for people with thalassaemia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Beta Thalassemia 5. Infant 1 to 23 mo 6. Alpha Thalassemia 7. Thalassemia 8. Aged 65-79 years 9. Adolescent 13-18 years 10. Adult 19-44 years 11. Middle Aged 45-64 years 12. Young Adult 19-24 years 13. Birth to 1 mo
Provide patient population that should be included in the study
Vitamin D supplementation for sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Hemoglobin SS Disease 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Gene therapy for haemophilia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Haemophilia 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for preventing silent cerebral infarcts in people with sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Sickle Cell-beta-thalassemia 5. Infant 1 to 23 mo 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Adult 19-44 years 9. Middle Aged 45-64 years 10. Young Adult 19-24 years 11. Birth to 1 mo 12. Hemoglobin SS Disease 13. Sickle Cell-hemoglobin C Disease
Provide patient population that should be included in the study
Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Hemoglobin SS Disease 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Early erythropoiesis‐stimulating agents in preterm or low birth weight infants
1. Birth to 1 mo 2. Low Birth Weight Infant 3. Preterm Infant
Provide patient population that should be included in the study
Late erythropoiesis‐stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants
1. Birth to 1 mo 2. Low Birth Weight Infant 3. Preterm Infant
Provide patient population that should be included in the study
Blood transfusions for treating acute chest syndrome in people with sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Acute Chest Syndrome 10. Aged 65-79 years 11. Hemoglobin SS Disease 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Intravenous iron therapy for non‐anaemic, iron‐deficient adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Iron Deficiency Without Anemia 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Treatment of dental complications in sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Dental Disorder 10. Aged 65-79 years 11. Hemoglobin SS Disease 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Treatment for avascular necrosis of bone in people with sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Avascular Necrosis Of Bone 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Multiple chronic conditions 9. Adult 19-44 years 10. Middle Aged 45-64 years 11. Young Adult 19-24 years 12. Birth to 1 mo 13. Hemoglobin SS Disease
Provide patient population that should be included in the study
Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use undergoing non‐cardiac surgery or invasive procedures
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Abnormal Coagulation Profile 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: a network meta‐analysis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Multiple Myeloma
Provide patient population that should be included in the study
Pharmacological interventions for painful sickle cell vaso‐occlusive crises in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Pain 5. Young Adult 19-24 years 6. Hemoglobin SS Disease With Vasoocclusive Crisis 7. Aged 65-79 years
Provide patient population that should be included in the study
Statins for children with familial hypercholesterolemia
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Familial Hypercholesterolemia - Heterozygous 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Regular long‐term red blood cell transfusions for managing chronic chest complications in sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Acute Chest Syndrome 10. Aged 65-79 years 11. Hemoglobin SS Disease 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotics for treating osteomyelitis in people with sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Osteomyelitis 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Hemoglobin SS Disease 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Splenectomy for people with thalassaemia major or intermedia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Thalassemia Intermedia 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Thalassemia Major 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Magnesium for treating sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Beta Thalassemia 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Hemoglobin SS Disease 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Procedure On Oral Cavity 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Adult 19-44 years 9. Middle Aged 45-64 years 10. Congenital Von Willebrand's Disease 11. Haemophilia 12. Young Adult 19-24 years 13. Birth to 1 mo
Provide patient population that should be included in the study
Hydroxyurea (hydroxycarbamide) for transfusion‐dependent β‐thalassaemia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Beta Thalassemia 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Blood Product Transfusion Dependent 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Blood Coagulation Disorder 4. Young Adult 19-24 years 5. Pregnancy 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Aerobic physical exercise for adult patients with haematological malignancies
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Hematological Malignancy 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Hemopoietic Stem Cell Transplant 6. Acute Graft-versus-host Disease 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Adult 19-44 years 10. Blood disorders 11. Middle Aged 45-64 years 12. Young Adult 19-24 years 13. Birth to 1 mo 14. Chronic Graft-versus-host Disease
Provide patient population that should be included in the study
Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Neutropenic Disorder 5. Infant 1 to 23 mo 6. Aged 65-79 years 7. Fever 8. Adolescent 13-18 years 9. Adult 19-44 years 10. Chemotherapy 11. Middle Aged 45-64 years 12. Young Adult 19-24 years 13. Birth to 1 mo 14. Antibiotic Therapy
Provide patient population that should be included in the study
Pro‐coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Haemorrhage 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Vaccines for preventing invasive salmonella infections in people with sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Hemoglobin SS Disease 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Insecticide‐treated nets for preventing malaria
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Prevention Of Malaria 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Drugs for preventing red blood cell dehydration in people with sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Hemoglobin SS Disease 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Prophylactic platelet transfusions prior to surgery for people with a low platelet count
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Low platelet count 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Conjugate Haemophilus influenzae type b vaccines for sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Hemoglobin SS Disease 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Effects of all‐trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (non‐APL))
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Acute Myelocytic Leukemia 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Comparison of a therapeutic‐only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Bone Marrow Disorder 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Folate supplementation in people with sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Hemoglobin SS Disease 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Mosquito repellents for malaria prevention
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Prevention Of Malaria 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years 12. Malaria-endemic area
Provide patient population that should be included in the study
Bisphosphonates in multiple myeloma: an updated network meta‐analysis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Multiple Myeloma
Provide patient population that should be included in the study
Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in patients with solid tumours
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Solid Tumor 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Hemoglobin SS Disease 11. Acute Sickle Cell Splenic Sequestration Crisis 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Hematopoietic stem cell transplantation for Gaucher disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Gaucher's Disease 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Prophylactic intravenous calcium therapy for exchange blood transfusion in the newborn
1. Neonatal Exchange Blood Transfusion 2. Neonate 3. Birth to 1 mo
Provide patient population that should be included in the study
Thrombopoietin mimetics for patients with myelodysplastic syndromes
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Myelodysplastic Syndrome 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years